DE60045082D1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents
Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutyninInfo
- Publication number
- DE60045082D1 DE60045082D1 DE60045082T DE60045082T DE60045082D1 DE 60045082 D1 DE60045082 D1 DE 60045082D1 DE 60045082 T DE60045082 T DE 60045082T DE 60045082 T DE60045082 T DE 60045082T DE 60045082 D1 DE60045082 D1 DE 60045082D1
- Authority
- DE
- Germany
- Prior art keywords
- oxybutynin
- desethyloxybutynin
- smooth muscle
- optically pure
- musculatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/015515 WO2001093683A1 (en) | 2000-06-07 | 2000-06-07 | Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60045082D1 true DE60045082D1 (de) | 2010-11-18 |
Family
ID=21741461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60045082T Expired - Lifetime DE60045082D1 (de) | 2000-06-07 | 2000-06-07 | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1286591B1 (de) |
JP (1) | JP5684964B2 (de) |
CN (3) | CN1454054A (de) |
AT (1) | ATE483459T1 (de) |
AU (2) | AU5596600A (de) |
CA (1) | CA2378754A1 (de) |
DE (1) | DE60045082D1 (de) |
ES (1) | ES2350330T3 (de) |
WO (1) | WO2001093683A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1455776A4 (de) * | 2001-12-21 | 2006-05-17 | Bridge Pharma Inc | Nicht-arrhythmogener metabolit von oxybutynin |
EP1424079A1 (de) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors |
PT1629850E (pt) * | 2004-08-24 | 2007-08-14 | Nutricia Nv | Composição nutricional que compreende a administração de oligossacarídeos indigeríveis |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
KR20190060879A (ko) | 2011-03-02 | 2019-06-03 | 제롬 쉔타그 | 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단 |
US10238602B2 (en) | 2011-06-03 | 2019-03-26 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies |
US10349884B2 (en) | 2011-06-03 | 2019-07-16 | Sighpath Pharma Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
US8753674B2 (en) | 2011-06-03 | 2014-06-17 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current |
US10449193B2 (en) | 2011-06-03 | 2019-10-22 | Signpath Pharma Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies |
US10117881B2 (en) | 2011-06-03 | 2018-11-06 | Signpath Pharma, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies |
US20160151321A1 (en) | 2012-11-13 | 2016-06-02 | Dinesh C. Patel | Methods for the treatment of sialorrhea |
US20140135392A1 (en) * | 2012-11-13 | 2014-05-15 | NeuRx Pharmaceuticals LLC | Methods for the treatment of sialorrhea |
CN103169660B (zh) * | 2013-04-15 | 2015-04-08 | 石正国 | 一种制备高包封率的利巴韦林脂质体口服乳 |
CA2933204C (en) | 2013-12-18 | 2020-04-28 | Signpath Pharma, Inc. | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel |
AU2015269699B2 (en) | 2014-06-03 | 2020-08-13 | Avanti Polar Lipids, Inc. | Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies |
KR102638618B1 (ko) | 2016-04-27 | 2024-02-21 | 사인패스 파마 인코포레이티드 | 약물 유발된 방실 차단의 방지 |
BR112022026880A2 (pt) * | 2020-07-03 | 2023-03-14 | Phoxbio Ltd | Redução de infecções virais |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4008269A (en) * | 1970-05-05 | 1977-02-15 | William H. Rorer, Inc. | Phenylacetic acids |
IT1231237B (it) * | 1987-09-21 | 1991-11-26 | Angeli Inst Spa | Derivati eterociclici |
US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
US5973182A (en) * | 1998-10-22 | 1999-10-26 | Sepracor Inc. | Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters |
-
2000
- 2000-06-07 AU AU5596600A patent/AU5596600A/xx active Pending
- 2000-06-07 CA CA002378754A patent/CA2378754A1/en not_active Abandoned
- 2000-06-07 JP JP2002501260A patent/JP5684964B2/ja not_active Expired - Fee Related
- 2000-06-07 ES ES00941235T patent/ES2350330T3/es not_active Expired - Lifetime
- 2000-06-07 EP EP00941235A patent/EP1286591B1/de not_active Expired - Lifetime
- 2000-06-07 AT AT00941235T patent/ATE483459T1/de not_active IP Right Cessation
- 2000-06-07 CN CN00819623A patent/CN1454054A/zh active Pending
- 2000-06-07 CN CNA2007101418683A patent/CN101108176A/zh active Pending
- 2000-06-07 WO PCT/US2000/015515 patent/WO2001093683A1/en active IP Right Grant
- 2000-06-07 DE DE60045082T patent/DE60045082D1/de not_active Expired - Lifetime
- 2000-06-07 AU AU2000255966A patent/AU2000255966B2/en not_active Expired
-
2003
- 2003-05-16 CN CN03131438A patent/CN1451388A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AU5596600A (en) | 2001-12-17 |
EP1286591A1 (de) | 2003-03-05 |
CA2378754A1 (en) | 2001-12-13 |
CN101108176A (zh) | 2008-01-23 |
WO2001093683A1 (en) | 2001-12-13 |
CN1454054A (zh) | 2003-11-05 |
AU2000255966A1 (en) | 2002-03-07 |
JP5684964B2 (ja) | 2015-03-18 |
EP1286591A4 (de) | 2007-04-04 |
AU2000255966B2 (en) | 2005-03-24 |
EP1286591B1 (de) | 2010-10-06 |
ES2350330T3 (es) | 2011-01-21 |
ATE483459T1 (de) | 2010-10-15 |
CN1451388A (zh) | 2003-10-29 |
JP2003535110A (ja) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60045082D1 (de) | Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin | |
BRPI0506970A (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
DE60027769D1 (de) | Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase | |
NO20054296D0 (no) | Anvendelse av palonosetron for behandling av kvalme og oppkast etter kirurgisk inngrep | |
MXPA03011707A (es) | Compuestos heterobiciclicos sustituidos con triamida. | |
PL374865A1 (en) | Treatment of tnf alpha related disorders | |
MX2007002470A (es) | Fenilaminotiazoles sustituidos y su uso. | |
CO4790154A1 (es) | Compuestos heterociclicos como inhibidores de enzimas rota- masas | |
DK0786991T3 (da) | Polyaminforbindelsre til behandling af proliferative karsygdomme | |
NO20041166L (no) | Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament | |
SE0104331D0 (sv) | Novel compounds | |
WO2001087849A3 (en) | Modulators of tnf- alpha signaling | |
DE60025639D1 (de) | Substituierte diazepan | |
BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
DK1744736T3 (da) | Fremgangsmåde til behandling af problemer med tørre øjne og uveitis | |
EA200400793A1 (ru) | Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции | |
CY1106409T1 (el) | Παραγωγα κινολινης | |
WO2004098599A3 (en) | Proton pump inhibitors for the treatment of lower abdominal disorders | |
NO20032406D0 (no) | Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens | |
WO2003092611A3 (en) | Methods of inducing formation of functional and organized lymphatic vessels | |
DK1152760T3 (da) | Anvendelse af 4-aminopyridin til behandling af perifere neuropatier | |
NO20042138L (no) | Forbindelser og fremgangsmate for behandling av hyperaktiv blaere | |
DK1368023T3 (da) | Anvendelse af buprenoprphin til behandling af urininkontinens | |
NZ511997A (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
IT1320192B1 (it) | Composizione terapeutica per la cura della psoriasi. |